ADS-5102 (Amantadine) Extended-Release Capsules for Levodopa-Induced Dyskinesia in Parkinson Disease (EASE LID Study): A Randomized Clinical Trial

No abstract is available for this paper.

• Publication year

  2017

• Venue

  JAMA Neurology

• Publication date

  2017-08-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1001/jamaneurol.2017.0943PMID 28604926PMCID PMC5710325
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Mavoglurant (AFQ056) in combination with increased levodopa dosages in Parkinson's disease patients

  2016cited by this paper
• Amantadine extended release for levodopa‐induced dyskinesia in Parkinson's disease (EASED Study)

  2015cited by this paper
• Handling missing values in the MDS‐UPDRS

  2015cited by this paper
• Falls in ambulatory non-demented patients with Parkinson’s disease

  2015cited by this paper
• Withdrawing amantadine in dyskinetic patients with Parkinson disease

  2014cited by this paper
• Quality of life in Parkinson's disease patients with motor fluctuations and dyskinesias in five European countries.

  2014cited by this paper
• Mini‐Mental State Examination

  2014cited by this paper
• Withdrawing amantadine in dyskinetic patients with Parkinson disease: The AMANDYSK trial

  2014cited by this paper
• World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects.

  2014cited by this paper
• World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects.

  2013cited by this paper
• Traditional multiplicity adjustment methods in clinical trials

  2013cited by this paper
• Which dyskinesia scale best detects treatment response?

  2013cited by this paper
• Treatment patterns and associated costs with Parkinson's disease levodopa induced dyskinesia.

  2012cited by this paper
• Patient and caregiver perceptions of the social impact of advanced Parkinson’s disease and dyskinesias

  2012cited by this paper
• Randomized clinical trial of fipamezole for dyskinesia in Parkinson disease (FJORD study)

  2012cited by this paper
• Determination of minimal clinically important change in early and advanced Parkinson's disease

  2011cited by this paper
• Long‐term antidyskinetic efficacy of amantadine in Parkinson's disease

  2010cited by this paper
• Task force report on scales to assess dyskinesia in Parkinson's disease: Critique and recommendations

  2010cited by this paper
• Evaluation of the Abuse Potential of Extended Release Hydromorphone Versus Immediate Release Hydromorphone

  2010cited by this paper
• Smoking produces rapid rise of [11C]nicotine in human brain

  2010cited by this paper
• Hallucinations in Parkinson disease

  2009cited by this paper
• Levodopa-Induced Dyskinesias in Parkinson’s Disease: Etiology, Impact on Quality of Life, and Treatments

  2008cited by this paper
• Levodopa-induced dyskinesias and their management

  2008cited by this paper
• The Unified Dyskinesia Rating Scale: Presentation and clinimetric profile

  2008cited by this paper
• Placebo influences on dyskinesia in Parkinson's disease

  2008cited by this paper
• Levodopa-induced dyskinesia in Parkinson’s disease: clinical features, pathogenesis, prevention and treatment

  2007cited by this paper
• Movement Disorder Society‐sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS‐UPDRS): Process, format, and clinimetric testing plan

  2007cited by this paper
• Projected number of people with Parkinson disease in the most populous nations, 2005 through 2030.

  2007cited by this paper
• Translation of nondopaminergic treatments for levodopa‐induced dyskinesia from MPTP‐lesioned nonhuman primates to phase IIa clinical studies: Keys to success and roads to failure

  2006cited by this paper
• PET study examining pharmacokinetics, detection and likeability, and dopamine transporter receptor occupancy of short- and long-acting oral methylphenidate.

  2006cited by this paper
• Blockade of glutamatergic transmission as treatment for dyskinesias and motor fluctuations in Parkinson's disease

  2005cited by this paper
• Amantadine reduces the duration of levodopa-induced dyskinesia: a randomized, double-blind, placebo-controlled study.

  2005cited by this paper
• Duration of amantadine benefit on dyskinesia of severe Parkinson's disease.

  2004cited by this paper
• Parkinson's disease home diary: Further validation and implications for clinical trials

  2004cited by this paper
• Amantadine for dyskinesia in Parkinson's disease.

  2003cited by this paper
• Pharmacokinetic and pharmacodynamic properties of stimulants: implications for the design of new treatments for ADHD.

  2002cited by this paper
• Amantadine for dyskinesia in patients affected by severe Parkinson's disease

  2001cited by this paper
• [Mini-mental state examination].

  2001cited by this paper
• Optimally weighted, fixed sequence and gatekeeper multiple testing procedures

  2001cited by this paper
• Frequency of levodopa‐related dyskinesias and motor fluctuations as estimated from the cumulative literature

  2001cited by this paper
• A Home Diary to Assess Functional Status in Patients with Parkinson's Disease with Motor Fluctuations and Dyskinesia

  2000cited by this paper
• The Effect of Amantadine on Levodopa-induced Dyskinesias in Parkinson's Disease: A Double-blind, Placebo-controlled Study

  2000cited by this paper
• Beneficial effects of amantadine on L‐dopa‐induced dyskinesias in Parkinson's disease

  2000cited by this paper
• Transient benefit of amantadine in Parkinson's disease: The facts about the myth

  1999cited by this paper
• Amantadine for levodopa-induced dyskinesias: a 1-year follow-up study.

  1999cited by this paper
• Dopamine transporter occupancies in the human brain induced by therapeutic doses of oral methylphenidate.

  1998cited by this paper
• Amantadine as treatment for dyskinesias and motor fluctuations in Parkinson's disease

  1998cited by this paper
• Amantadine reduces levodopa‐induced dyskinesias in parkinsonian monkeys

  1998cited by this paper
• Aminoadamantanes as NMDA receptor antagonists and antiparkinsonian agents--preclinical studies.

  1997cited by this paper
• Amantadine in parkinsonian patients unresponsive to levodopa: a pilot study

  1996cited by this paper
• Cocaine addiction: hypothesis derived from imaging studies with PET.

  1996cited by this paper
• Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases.

  1992cited by this paper
• Clinical Pharmacokinetics of Amantadine Hydrochloride

  1988cited by this paper
• Comparative Single-Dose Pharmacokinetics of Amantadine Hydrochloride and Rimantadine Hydrochloride in Young and Elderly Adults

  1986cited by this paper
• Amantadine kinetics in healthy elderly men: Implications for influenza prevention

  1985cited by this paper
• Prophylactic amantadine dose and plasma concentration—effect relationships in healthy adults

  1985cited by this paper
• Comparative toxicity of amantadine hydrochloride and rimantadine hydrochloride in healthy adults

  1981cited by this paper
• Amantadine kinetics in healthy young subjects after long‐term dosing

  1979cited by this paper
• Amantadine in Parkinson's disease. Review of more than two years' experience.

  1972cited by this paper
• [Amantadine in the treatment of Parkinson's disease].

  1972cited by this paper
• Double blind study using amantadine hydrochloride in the therapy of Parkinson's disease.

  1971cited by this paper
• Double blind study using amantadine hydrochloride in the therapy of Parkinson's disease.

  1971cited by this paper
• Amantadine dosage in treatment of Parkinson's disease.

  1970cited by this paper
• Use of Amantadine in Parkinson's Disease. Results of a Double-blind Trial

  1970cited by this paper
• The toxicologic and pharmacologic properties of amantadine hydrochloride.

  1969cited by this paper
• Amantadine in the treatment of Parkinson's disease.

  1969cited by this paper
• Absorption, distribution and excretion of amantadine hydrochloride.

  1965cited by this paper
• Studies on the antiviral activity of 1-adamantanamine.

  1965cited by this paper

• Research Trends and Hotspots in Levodopa-induced Dyskinesia: A Bibliometric Analysis (2015-2024)

  2026cites this paper
• A meta-analysis of the long-term efficacy of Amantadine for Levodopa-induced dyskinesia in Parkinson’s disease

  2025cites this paper
• Treatment strategies for motor fluctuations in Parkinson’s disease: a systematic review of efficacy, functionality, and drug accessibility with a focus on Latin America

  2025cites this paper
• Parkinson's disease in transition: Genetics, biomarkers, and emerging therapeutics.

  2025cites this paper
• Comparative Safety of Istradefylline Among Parkinson Disease Adjunctive Therapies: A Systematic Review and Meta-analysis of Randomized Controlled Studies

  2025cites this paper
• Neurophysiological Treatment Effects of Mesdopetam, Pimavanserin and Amantadine in a Rodent Model of Levodopa‐Induced Dyskinesia

  2025cites this paper
• Moving to a non-dopaminergic approach for the treatment of OFF fluctuations in Parkinson’s disease

  2025cites this paper
• Update on Treatments for Parkinson's Disease Motor Fluctuations – An International Parkinson and Movement Disorder Society Evidence‐Based Medicine Review

  2025cites this paper
• Advances in the Pharmacological Management of Parkinson’s Disease

  2025cites this paper
• OAB-14 Attenuated Glymphatic System Disorder, Neuroinflammation and Dyskinesia in Parkinson’s Disease Model Mice Induced by Rotenone

  2025cites this paper
• Pharmacological therapies for early and long-term recovery in disorders of consciousness: current knowledge and promising avenues

  2025cites this paper
• CircPRDM5-mediated regulation of miR-433-3p and HDAC6 in Parkinson's disease: a novel neuroprotective axis

  2025cites this paper
• Targeting the serotonergic system in the treatment of neurodegenerative diseases—emerging therapies and unmet challenges

  2025cites this paper
• Mesdopetam for the Treatment of Levodopa Induced Dyskinesia in Parkinson's Disease: A Randomized Phase 2b Trial

  2025cites this paper
• Efficacy and safety of oral amantadine in Parkinson’s disease with dyskinesia and motor fluctuations: a systematic review and meta-analysis of randomised controlled trials

  2025cites this paper
• Therapeutic Approaches in Movement Disorders: A Narrative Review

  2025cites this paper
• Recent and on-going trials for the treatment of levodopa-induced dyskinesia: a review of the clinical trial databases.

  2025cites this paper
• Unmet needs in the pharmacological management of motor symptoms in Parkinson's disease.

  2025cites this paper
• Efficacy and Safety of Twelve Anti‐Dyskinetic Drugs in Parkinson's Disease: A Bayesian Network Meta‐Analysis of Randomized Controlled Trials

  2025cites this paper
• Accurate Neurotransmitter Release by Ultrasound‐Responsive Nanomaterials for Alleviating L‐DOPA‐Induced Dyskinesia in Parkinson's Disease

  2025cites this paper
• Using artificial intelligence to identify drugs for repurposing to treat l-DOPA-induced dyskinesia.

  2024cites this paper
• Continuous subcutaneous levodopa-carbidopa infusion for Parkinson's disease.

  2024cites this paper
• Trihexyphenidyl has a psychostimulant-like effect on mice

  2024cites this paper
• Aktuelle Therapiestrategien motorischer Symptome einer Parkinsonkrankheit

  2024cites this paper
• Efficacy and safety of Tianqi Pingchan Granule, a compound Chinese herbal medicine, for levodopa-induced dyskinesia in Parkinson's disease: A randomized double-blind placebo-controlled trial.

  2024cites this paper
• A bioactive sprite: Recent advances in the application of vinyl sulfones in drug design and organic synthesis.

  2024cites this paper
• Extended-release amantadine for OFF-related dystonia in Parkinson's disease.

  2024cites this paper
• Novel and experimental therapeutics for the management of motor and non-motor Parkinsonian symptoms

  2024cites this paper
• Altered Amantadine Effects after Repetitive Treatment for l-dopa-induced Involuntary Movements in a Rat Model of Parkinson's Disease.

  2023cites this paper
• The Clinical Development of Levodopa Inhalation Powder

  2023cites this paper
• Comparative efficacy and safety of adjunctive drugs to levodopa for fluctuating Parkinson’s disease - network meta-analysis

  2023cites this paper
• Adverse effects of medications used to treat motor symptoms of Parkinson′s disease: A narrative review

  2023cites this paper
• Safety review of current pharmacotherapies for levodopa-treated patients with Parkinson’s disease

  2023cites this paper
• Targeting Sigma Receptors for the Treatment of Neurodegenerative and Neurodevelopmental Disorders

  2023cites this paper
• Pharmacological Treatment of Tremor in Parkinson’s Disease Revisited

  2023cites this paper
• Amantadine delayed release/extended release capsules significantly reduce OFF time in Parkinson’s disease

  2022cites this paper
• Doxycycline to treat levodopa-induced dyskinesias in Parkinson's disease: a preliminary study

  2022cites this paper
• Amantadine delayed release/extended release capsules significantly reduce OFF time in Parkinson’s disease

  2022cites this paper
• Clinically important change on the Unified Dyskinesia Rating Scale among patients with Parkinson's disease experiencing dyskinesia

  2022cites this paper
• Chorea

  2022cites this paper
• Preclinical reserpine models recapitulating motor and non-motor features of Parkinson’s disease: Roles of epigenetic upregulation of alpha-synuclein and autophagy impairment

  2022cites this paper
• Development of N,N-Dimethylglycine-Amantadine for Adjunctive Dopaminergic Application: Synthesis, Structure and Biological Activity

  2022cites this paper
• Should “on-demand” treatments for Parkinson’s disease OFF episodes be used earlier?

  2022cites this paper
• How I treat Parkinson's disease

  2022cites this paper
• Newly Approved and Investigational Drugs for Motor Symptom Control in Parkinson's Disease

  2022cites this paper
• Amantadine extended release capsules (GOCOVRI®) in Parkinson’s disease: a profile of its use in the USA

  2022influential citation
• Altered neural cell junctions and ion-channels leading to disrupted neuron communication in Parkinson’s disease

  2022cites this paper
• Glutamate modulation for the treatment of levodopa induced dyskinesia: a brief review of the drugs tested in the clinic.

  2022cites this paper
• The multimodal serotonin compound Vilazodone alone, but not combined with the glutamate antagonist Amantadine, reduces l-DOPA-induced dyskinesia in hemiparkinsonian rats.

  2022cites this paper
• Molecular Mechanisms and Therapeutic Strategies for Levodopa-Induced Dyskinesia in Parkinson’s Disease: A Perspective Through Preclinical and Clinical Evidence

  2022cites this paper
• Non-dopaminergic approaches to the treatment of motor complications in Parkinson's disease.

  2022cites this paper
• Immediate-release/extended-release amantadine (OS320) to treat Parkinson's disease with levodopa-induced dyskinesia: Analysis of the randomized, controlled ALLAY-LID studies.

  2022cites this paper
• An Update on Nondopaminergic Treatments for Motor and Non-motor Symptoms of Parkinson’s Disease

  2022cites this paper
• Recent Advances in Drug Therapy for Parkinson's Disease

  2022cites this paper
• Levodopa-induced dyskinesia: a historical review of Parkinson’s disease, dopamine, and modern advancements in research and treatment

  2022cites this paper
• A Review of Randomized Phase III Pharmacological Clinical Trials for Motor Symptoms in Parkinson’s Disease Patients and Quality of Evidence Recommendations

  2021cites this paper
• Clinical Trials In Parkinson's Disease

  2021influential citation
• GOCOVRI® (amantadine) extended-release capsules in Parkinson's disease.

  2021cites this paper
• Potential utility of amantadine DR/ER in persons with Parkinson’s disease meeting 5-2-1 criteria for device aided therapy

  2021cites this paper
• Selected natural and synthetic agents effective against Parkinson's disease with diverse mechanisms.

  2021cites this paper
• Development, Efficacy and Safety of Once-daily, Bedtime, Extended-release Amantadine (Gocovri®) to Treat Dyskinesia and OFF Time in Parkinson’s Disease

  2021influential citation
• Novel Therapeutic Interventions for Combating Parkinson's Disease and Prospects of Nose-to-Brain Drug Delivery.

  2021cites this paper
• Amantadine Revisited: A Contender for Initial Treatment in Parkinson’s Disease?

  2021cites this paper
• Current Knowledge on the Background, Pathophysiology and Treatment of Levodopa-Induced Dyskinesia—Literature Review

  2021cites this paper
• Medical treatment of the motor features of Parkinson disease

  2021cites this paper
• Profile and frequency of antiparkinsonian drugs adverse reactions: a systematic review and meta-analysis

  2021cites this paper
• Implications of dopaminergic medication withdrawal in Parkinson’s disease

  2021cites this paper
• Emerging Pharmacotherapies for Motor Symptoms in Parkinson’s Disease

  2021cites this paper
• An Update on Medical and Surgical Treatments of Parkinson’s Disease

  2021cites this paper
• Current Knowledge on the Background, Pathophysiology, and Treatment of Levodopa-Induced Dyskinesia – Literature Review.

  2021cites this paper
• Amantadine in the treatment of Parkinson's disease and other movement disorders.

  2021cites this paper
• Effects of Gocovri (Amantadine) Extended-Release Capsules on Motor Aspects of Experiences of Daily Living in People with Parkinson’s Disease and Dyskinesia

  2021influential citation
• Pathophysiological Mechanisms and Experimental Pharmacotherapy for L-Dopa-Induced Dyskinesia

  2021cites this paper
• Practical aspects of prescribing antiparkinsonian drugs. The place of amantadines in the management of Parkinson’s disease

  2021cites this paper
• Roles of the Functional Interaction between Brain Cholinergic and Dopaminergic Systems in the Pathogenesis and Treatment of Schizophrenia and Parkinson’s Disease

  2021cites this paper
• Effects of Gocovri (Amantadine) Extended Release Capsules on Non-Motor Symptoms in Patients with Parkinson’s Disease and Dyskinesia

  2021cites this paper
• Amantadine: an old drug reborn.

  2021cites this paper
• Amantadine ER (Gocovri®) Significantly Increases ON Time Without Any Dyskinesia: Pooled Analyses From Pivotal Trials in Parkinson's Disease

  2021cites this paper
• Istradefylline – a first generation adenosine A2A antagonist for the treatment of Parkinson’s disease

  2021cites this paper
• Clinical Trials for Motor Complications in Parkinson’s Disease

  2021cites this paper
• Update on Parkinson's Disease Therapy

  2021cites this paper
• Clinical Trials for in Parkinson’s

  2020cites this paper
• Optimisation des traitements classiques et nouvelles perspectives thérapeutiques dans la maladie de Parkinson

  2020cites this paper
• EASE LID 2: A 2-Year Open-Label Trial of Gocovri (Amantadine) Extended Release for Dyskinesia in Parkinson’s Disease

  2020cites this paper
• Utilization Patterns of Amantadine in Parkinson’s Disease Patients Enrolled in the French COPARK Study

  2020cites this paper
• Ondansetron, a highly selective 5-HT3 receptor antagonist, reduces L-DOPA-induced dyskinesia in the 6-OHDA-lesioned rat model of Parkinson's disease.

  2020cites this paper
• The highly selective mGlu2 receptor positive allosteric modulator LY‐487,379 alleviates l‐DOPA‐induced dyskinesia in the 6‐OHDA‐lesioned rat model of Parkinson's disease

  2020cites this paper
• Diagnosis and Treatment of Parkinson Disease: A Review.

  2020cites this paper
• Ameliorative effects of a phosphodiesterase 10A inhibitor, MR1916 on l-DOPA-induced dyskinesia in parkinsonian rats

  2020cites this paper
• Research advances on L-DOPA-induced dyskinesia: from animal models to human disease

  2020cites this paper
• Pharmacologic Treatment of Motor Symptoms Associated with Parkinson Disease.

  2020cites this paper
• Combined mGlu2 orthosteric stimulation and positive allosteric modulation alleviates l-DOPA-induced psychosis-like behaviours and dyskinesia in the parkinsonian marmoset

  2020cites this paper
• The mGlu2/3 antagonist LY-341,495 reverses the anti-dyskinetic and anti-psychotic effects of the mGlu2 activators LY-487,379 and LY-354,740 in the MPTP-lesioned marmoset

  2020cites this paper
• Safinamide for Treating Parkinson’s Disease

  2020cites this paper
• Therapeutic Strategies to Treat or Prevent Off Episodes in Adults with Parkinson’s Disease

  2020cites this paper
• Visual Hallucinations and the Role of Medications in Parkinson's Disease: Triggers, Pathophysiology, and Management.

  2020cites this paper
• Identification and optimization of piperine analogues as neuroprotective agents for the treatment of Parkinson's disease via the activation of Nrf2/keap1 pathway.

  2020cites this paper
• An investigation into the antidyskinetic and reinforcing effects of UWA-101 in Sprague Dawley rats

  2020cites this paper
• Parkinson’s Disease Multimodal Complex Treatment (PD-MCT): Analysis of Therapeutic Effects and Predictors for Improvement

  2020cites this paper
• Parkinson’s disease: etiopathogenesis and treatment

  2020cites this paper